Research programme: cognition/schizophrenia - AGY Therapeutics
Latest Information Update: 10 Oct 2006
At a glance
- Originator AGY Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders; Schizophrenia
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Cognition disorders in USA (unspecified route)
- 10 Oct 2006 Discontinued - Preclinical for Schizophrenia in USA (unspecified route)
- 23 Aug 2004 This programme is available for licensing (http://www.agyinc.com)